Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Ejection fraction decreased? 107 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 107 reports of Ejection fraction decreased have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.0% of all adverse event reports for LENALIDOMIDE.

107
Reports of Ejection fraction decreased with LENALIDOMIDE
0.0%
of all LENALIDOMIDE reports
3
Deaths
46
Hospitalizations

How Dangerous Is Ejection fraction decreased From LENALIDOMIDE?

Of the 107 reports, 3 (2.8%) resulted in death, 46 (43.0%) required hospitalization, and 8 (7.5%) were considered life-threatening.

Is Ejection fraction decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 107 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Ejection fraction decreased?

SACUBITRIL\VALSARTAN (2,551) TRASTUZUMAB (1,579) DOXORUBICIN (834) CYCLOPHOSPHAMIDE (754) PERTUZUMAB (644) DOCETAXEL (520) PACLITAXEL (466) BISOPROLOL (314) RITUXIMAB (296) CARVEDILOL (284)

Which LENALIDOMIDE Alternatives Have Lower Ejection fraction decreased Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Ejection fraction decreased Reports All Drugs Causing Ejection fraction decreased LENALIDOMIDE Demographics